Varenicline for cognitive impairment in people with schizophrenia: systematic review and meta-analysis
People with schizophrenia frequently have cognitive dysfunction, which does not respond to pharmacological interventions. Varenicline has been identified as a potential treatment option for nicotinic receptor dysfunction with a potential to treat cognitive impairment in schizophrenia.
We conducted a systematic review of Pubmed, Embase, Psycinfo, CINAHL and the Cochrane Schizophrenia Trial Registry for randomised controlled trials of varenicline in people with schizophrenia for cognitive dysfunction. We excluded trials among people with dementia. We then undertook a meta-analysis with the primary outcome of difference in change of cognitive measures between varenicline and placebo as well as secondary outcomes of difference in rates of adverse events. We conducted a sensitivity analysis on smoking status and study duration.
We included four papers in the meta-analysis (n = 339). Varenicline was not superior to placebo for overall cognition (SMD = −0.022, 95% CI −0.154–0.110; Z = −0.333; p = 0.739), attention (SMD = −0.047, 95% CI −0.199–0.104; Z = −0.613; p = 0.540), executive function (SMD = −0.060, 95% CI −0.469–0.348; Z =− 0.290; p = 0.772) or processing speed (SMD = 0.038, 95% CI −0.232–0.308; Z = 0.279; p = 0.780). There was no difference in psychotic symptoms, but varenicline was associated with higher rates of nausea. Sensitivity analyses for smoking status and study duration did not alter the results.
Within the present literature, varenicline does not appear to be a useful target compound for improving cognitive impairment in schizophrenia. Based on these results, a trial would need over 2500 participants to be powered to show statistically significant findings.
KeywordsSchizophrenia cognition Varenicline Systematic review Meta-analysis
DS is supported in part by a National Health and Medical Research Council (NHMRC) Early Career Fellowship (GNT1111136). SLR holds a Senior Research Fellowship from NHMRC (GNT1154651).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Carruthers SP, Gurvich CT, Meyer D, Bousman C, Everall IP, Neill E, Pantelis C, Sumner PJ, Tan EJ, Thomas EH (2019) Exploring heterogeneity on the Wisconsin card sorting test in schizophrenia spectrum disorders: a cluster analytical investigation. J Int Neuropsychol Soc 1–11Google Scholar
- Conners CK, Staff M, Connelly V, Campbell S, Maclean M, Barnes J (2000) Conners’ continuous performance Test II (CPT II v. 5). Multi-Health Syst Inc 29:175–196Google Scholar
- Heaton RK, Staff P (1993) Wisconsin card sorting test: computer version 2. Odessa Psychol Assess Resour 4:1–4Google Scholar
- Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane CollaborationGoogle Scholar
- Hong LE, Thaker GK, Mcmahon RP, Summerfelt A, Rachbeisel J, Fuller RL, Wonodi I, Buchanan RW, Myers C, Heishman SJ, Yang J, Nye A (2011) Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 68:1195–1206CrossRefGoogle Scholar
- Kishi T, Ikuta T, Oya K, Matsunaga S, Matsuda Y, Iwata N (2018) Anti-dementia drugs for psychopathology and cognitive impairment in schizophrenia: a systematic review and meta-analysis. Int J NeuropsychopharmacolGoogle Scholar
- Lezak MD, Howieson DB, Loring DW, Fischer JS (2004) Neuropsychological assessment. Oxford University Press, USAGoogle Scholar
- Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, Lee SW, Kong BG, Kang JW, Oh MK, Kim SD, Mcmahon RP, Kelly DL (2012) Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37:660–668CrossRefGoogle Scholar
- Smith RC, Amiaz R, Si TM, Maayan L, Jin H, Boules S, Sershen H, Li C, Ren J, Liu Y, Youseff M, Lajtha A, Guidotti A, Weiser M, Davis JM (2016) Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia: a double-blind randomized trial. PLoS One 11:e0143490CrossRefGoogle Scholar
- Wechsler D (1981) Manual for the Wechsler adult intelligence scale-revised. Psychological Corporation, New York, p 198Google Scholar